Bridgebio Pharma Inc (BBIO)

$52.86 -0.42 (-0.79%)
Market Cap 10.19B
Revenue (ttm) 221.90M
Net Income (ttm) -535.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -241.44%
Debt to Equity Ratio -1.04
Volume 1,415,100
Avg Vol 2,531,892
Day's Range N/A - N/A
Shares Out 191.17M
Stochastic %K 81%
Beta 1.36
Analysts Strong Sell
Price Target $65.24

Company Profile

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 doub...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 391 9740
Address:
3160 Porter Drive, Suite 250, Palo Alto, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 3:09 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BBIO Current Share Price: $52.86 Contracts: $BBIO January 15, 2027 $55 Calls Scale in: $12.58- $15.37 Scale out: $19.57-$25.16 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 4 at 1:00 AM
Enter: $BBIO NOV 21 2025 $55 CALLS Buy in Price: $4.50 - $4.62 Take Profit: $10.95 Stop Bleeding: $4.07 ROI Potential: 137% Exit Within: 215 Minutes https://moneygroup.us/alerts
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Oct. 3 at 11:48 PM
$NTLA $ASTS $CRML $OKLO $BBIO Give me a better 4 month return 🔥🔥🔥🚀🚀🚀 Next 4 months watch the following make a similar move. Skye Mvis Alt Bbai Alms Beam
1 · Reply
JarvisFlow
JarvisFlow Oct. 3 at 4:27 PM
JP Morgan has adjusted their stance on BridgeBio Pharma ( $BBIO ), setting the rating to Overweight with a target price of 58 → 55.
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 8:17 AM
$BBIO: Unusual Options Activity Alerted CALL flow observed 15x contracts at Strike price of $30 Exp on 01/16/2026 with Premium of $37K and showing BEARISH Sentiment
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 2 at 12:50 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BBIO Current Share Price: $53.48 Contracts: $BBIO January 15, 2027 $55 Calls Scale in: $12.98- $15.87 Scale out: $20.20-$25.97 Can Easily Capture: 60% ROI Blended DTE: 471 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
RonIsWrong
RonIsWrong Oct. 1 at 7:12 PM
$BBIO
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 1 at 4:54 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BBIO Current Share Price: $51.94 Contracts: $BBIO January 15, 2027 $55 Calls Scale in: $11.97- $14.63 Scale out: $18.62-$23.94 Can Easily Capture: 60% ROI Blended DTE: 471 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
PepCF
PepCF Sep. 30 at 7:36 PM
$KALA C’mon!! Baker Bros is the fund with the most shares — the same one that grabbed SMMT at 9 bucks. Looks just like what went down with $BBIO and $CABA.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Sep. 30 at 4:05 PM
$BBIO $ALNY $PFE I have been slightly off target... i suspect it will eventually run to 75 by end of year.
1 · Reply
Latest News on BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 3, 2025, 4:01 PM EDT - 1 day ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

Sep 28, 2025, 11:15 AM EDT - 6 days ago

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025

Sep 22, 2025, 7:30 AM EDT - 12 days ago

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025

BridgeBio Pharma, Inc. (BBIO) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call (Transcript)

Sep 10, 2025, 12:33 PM EDT - 24 days ago

BridgeBio Pharma, Inc. (BBIO) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call (Transcript)

BridgeBio Pharma, Inc. (BBIO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 6:04 PM EDT - 26 days ago

BridgeBio Pharma, Inc. (BBIO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

Sep 6, 2025, 2:30 PM EDT - 4 weeks ago

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

Sep 3, 2025, 7:30 AM EDT - 4 weeks ago

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

Sep 2, 2025, 7:30 AM EDT - 4 weeks ago

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

Aug 30, 2025, 7:15 AM EDT - 5 weeks ago

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

BridgeBio to Participate in September Investor Conferences

Aug 27, 2025, 7:30 AM EDT - 5 weeks ago

BridgeBio to Participate in September Investor Conferences

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

Aug 25, 2025, 7:30 AM EDT - 5 weeks ago

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

‘BUY THAT THING': Historically undervalued stock now has value, says wealth expert

Aug 19, 2025, 5:30 PM EDT - 6 weeks ago

‘BUY THAT THING': Historically undervalued stock now has value, says wealth expert

BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 4:30 AM EDT - 2 months ago

BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

Aug 5, 2025, 4:01 PM EDT - 2 months ago

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

Jul 30, 2025, 12:37 PM EDT - 2 months ago

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

AMGN INSM

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

Jul 23, 2025, 7:30 AM EDT - 2 months ago

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

Jul 22, 2025, 7:30 AM EDT - 2 months ago

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jul 7, 2025, 6:29 PM EDT - 3 months ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BMRN GILD INSM XBI

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

Jun 30, 2025, 7:30 AM EDT - 3 months ago

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

Jun 26, 2025, 7:30 AM EDT - 3 months ago

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

BridgeBio: New Data Bolsters The Bull Case

Jun 4, 2025, 3:34 AM EDT - 4 months ago

BridgeBio: New Data Bolsters The Bull Case

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 2, 2025, 7:30 AM EDT - 4 months ago

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

May 20, 2025, 7:30 AM EDT - 4 months ago

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

May 19, 2025, 12:33 PM EDT - 4 months ago

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

May 13, 2025, 7:30 AM EDT - 5 months ago

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

May 12, 2025, 7:30 AM EDT - 5 months ago

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

May 7, 2025, 7:30 AM EDT - 5 months ago

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 9:43 PM EDT - 5 months ago

BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

Apr 29, 2025, 4:01 PM EDT - 5 months ago

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

Apr 28, 2025, 5:00 AM EDT - 5 months ago

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

BridgeBio: Early Signs Point To Blockbuster Revenues

Apr 22, 2025, 11:14 AM EDT - 5 months ago

BridgeBio: Early Signs Point To Blockbuster Revenues

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

Apr 22, 2025, 7:30 AM EDT - 5 months ago

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Mar 31, 2025, 10:00 AM EDT - 6 months ago

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

Mar 27, 2025, 3:20 PM EDT - 6 months ago

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

AZN

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

Mar 27, 2025, 7:00 AM EDT - 6 months ago

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

Mar 24, 2025, 7:30 AM EDT - 6 months ago

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

BridgeBio Announces CFO Succession

Mar 17, 2025, 4:01 PM EDT - 7 months ago

BridgeBio Announces CFO Succession

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

Feb 26, 2025, 2:49 AM EST - 7 months ago

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

Feb 24, 2025, 4:09 PM EST - 7 months ago

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

BridgeBio: Strong Start For Attruby

Feb 20, 2025, 1:34 PM EST - 8 months ago

BridgeBio: Strong Start For Attruby

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

Feb 20, 2025, 7:30 AM EST - 8 months ago

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

Feb 13, 2025, 4:01 PM EST - 8 months ago

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

Feb 11, 2025, 9:21 AM EST - 8 months ago

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

Top 4 Health Care Stocks You May Want To Dump In Q1

Jan 21, 2025, 6:06 AM EST - 9 months ago

Top 4 Health Care Stocks You May Want To Dump In Q1

BSX ISRG ITCI

BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval

Jan 15, 2025, 9:30 AM EST - 9 months ago

BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval

BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization

Jan 14, 2025, 3:40 PM EST - 9 months ago

BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

Jan 13, 2025, 11:00 AM EST - 9 months ago

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

Jan 8, 2025, 11:13 AM EST - 9 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BMY IOVA LLY MDGL MRK PFE

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

Jan 8, 2025, 7:30 AM EST - 9 months ago

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 3:09 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BBIO Current Share Price: $52.86 Contracts: $BBIO January 15, 2027 $55 Calls Scale in: $12.58- $15.37 Scale out: $19.57-$25.16 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 4 at 1:00 AM
Enter: $BBIO NOV 21 2025 $55 CALLS Buy in Price: $4.50 - $4.62 Take Profit: $10.95 Stop Bleeding: $4.07 ROI Potential: 137% Exit Within: 215 Minutes https://moneygroup.us/alerts
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Oct. 3 at 11:48 PM
$NTLA $ASTS $CRML $OKLO $BBIO Give me a better 4 month return 🔥🔥🔥🚀🚀🚀 Next 4 months watch the following make a similar move. Skye Mvis Alt Bbai Alms Beam
1 · Reply
JarvisFlow
JarvisFlow Oct. 3 at 4:27 PM
JP Morgan has adjusted their stance on BridgeBio Pharma ( $BBIO ), setting the rating to Overweight with a target price of 58 → 55.
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 8:17 AM
$BBIO: Unusual Options Activity Alerted CALL flow observed 15x contracts at Strike price of $30 Exp on 01/16/2026 with Premium of $37K and showing BEARISH Sentiment
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 2 at 12:50 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BBIO Current Share Price: $53.48 Contracts: $BBIO January 15, 2027 $55 Calls Scale in: $12.98- $15.87 Scale out: $20.20-$25.97 Can Easily Capture: 60% ROI Blended DTE: 471 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
RonIsWrong
RonIsWrong Oct. 1 at 7:12 PM
$BBIO
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 1 at 4:54 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BBIO Current Share Price: $51.94 Contracts: $BBIO January 15, 2027 $55 Calls Scale in: $11.97- $14.63 Scale out: $18.62-$23.94 Can Easily Capture: 60% ROI Blended DTE: 471 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
PepCF
PepCF Sep. 30 at 7:36 PM
$KALA C’mon!! Baker Bros is the fund with the most shares — the same one that grabbed SMMT at 9 bucks. Looks just like what went down with $BBIO and $CABA.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Sep. 30 at 4:05 PM
$BBIO $ALNY $PFE I have been slightly off target... i suspect it will eventually run to 75 by end of year.
1 · Reply
Quantumup
Quantumup Sep. 30 at 3:14 PM
Piper Sandler reiterated $BBIO at Overweight-$68 and said: We hosted a fireside chat with the mgmt team of BBIO and here are our main takeaways. $ALNY $PFE Piper Sanler added: The differentiated efficacy profile is helping support the strong launch dynamics for Attruby. For Q3, mgmt expects for Q3 to follow similar trends to Q2 in terms of free-drug and GTN. Additionally, mgmt reiterated they expect to capture 30-40% of the US ATTR-CM market at peak. The launch of Beyonttra (Attruby) in Germany was stronger compared to the US initially due to wide access at approval and has approximately ~47% of new Rx by 6 months in Germany. Lastly, topline data for Ph. 3 trial of encaleret and BBP-418 should come before Thanksgiving. In totality, it seems like a good set up for BBIO shares to outperform into YE.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Sep. 30 at 9:13 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BBIO Current Share Price: $51.54 Contracts: $BBIO January 15, 2027 $55 Calls Scale in: $11.90- $14.55 Scale out: $18.51-$23.80 Can Easily Capture: 60% ROI Blended DTE: 473 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
highnihilism
highnihilism Sep. 30 at 8:14 AM
$BBIO Bridgebio Pharma: 154 trades, $283K vs $781K avg (0.36x). $208K calls / $75K puts. $TT Trane Technologies: 118 trades, $258K vs $654K avg (0.39x). $208K calls / $49K puts. $DNN Denison Mines: 1,684 trades, $243K vs $262K avg (0.93x). $208K calls / $35K puts. $UBS UBS Group: 531 trades, $405K vs $455K avg (0.89x). $207K calls / $198K puts.
0 · Reply
DonCorleone77
DonCorleone77 Sep. 30 at 3:37 AM
$BBIO Information regarding TD Cowen analyst report on BBIO issued today: https://x.com/CorleoneDon77/status/1972866914213859535 cc: @RonIsWrong
0 · Reply
DonCorleone77
DonCorleone77 Sep. 30 at 3:36 AM
$BBIO Information regarding Piper Sandler analyst report on BBIO issued yesterday: https://x.com/CorleoneDon77/status/1972865385994100785 cc: @RonIsWrong
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 29 at 12:23 PM
$BBIO (+2.4% pre) Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM https://ooc.bz/l/78684
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 29 at 10:57 AM
WATCHLIST SEP 29 2025. $BBIO Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM $ENGS American Trust Investment Services Strengthens Executive Leadership Amid Accelerated Investment Banking Growth and Global Expansion $PHG Philips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025 $VYX Needham Reiterates Buy on NCR Voyix, Maintains $15 Price Target $ENLT Enlight Renewable Energy Secures $390M In Tax Equity Deals For Arizona Solar And Storage Project
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Sep. 29 at 6:59 AM
$BBIO blockbuster drug, 3 p3 trials pending readout, each alone can send it to $75, great management. One of my favorite positions.
0 · Reply
Jusar
Jusar Sep. 29 at 12:32 AM
$BBIO
0 · Reply
AlertsAndNews
AlertsAndNews Sep. 28 at 10:24 PM
$BBIO Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM- BridgeBio reported new exploratory results from the Phase 3 ATTRibute-CM trial showing acoramidis significantly reduced cumulative risk of cardiovascular mortality or recurrent cardiovascular hospitalization by 49% versus placebo through Month 30 (p<0.0001). Data showed 53 events avoided per 100 treated participants at Month 30, with benefits increasing over time.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Sep. 28 at 6:21 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BBIO Current Share Price: $50.05 Contracts: $BBIO January 15, 2027 $55 Calls Scale in: $10.06- $12.29 Scale out: $15.64-$20.12 Can Easily Capture: 60% ROI Blended DTE: 474 Days | Join Elites here: https://liquidtheta.com
0 · Reply
David_Stockett1836
David_Stockett1836 Sep. 28 at 6:01 AM
$BBIO what’s the word on this? Buyout rumors?
0 · Reply